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Atherosclerosis is a chronic inflammatory disease due to lipid deposition in the arterial wall. Multiple
mechanisms participate in the inflammatory process, including oxidative stress. Xanthine oxidase (XO) is a
major source of reactive oxygen species (ROS) and has been linked to the pathogenesis of atherosclerosis, but
the underlyingmechanisms remain unclear. Here, we show enhanced XO expression inmacrophages in the
atherosclerotic plaque and in aortic endothelial cells in ApoE2/2mice, and that febuxostat, a highly potent
XO inhibitor, suppressed plaque formation, reduced arterial ROS levels and improved endothelial
dysfunction in ApoE2/2 mice without affecting plasma cholesterol levels. In vitro, febuxostat inhibited
cholesterol crystal-induced ROS formation and inflammatory cytokine release in murine macrophages.
These results demonstrate that in the atherosclerotic plaque, XO-mediated ROS formation is
pro-inflammatory and XO-inhibition by febuxostat is a potential therapy for atherosclerosis.
A
therosclerosis is a chronic inflammatory disease of arteries secondary to lipid deposition in the vessel wall
and oxidative stress participates in its pathogenesis1–3. In the early phase of atherosclerosis, oxidative stress
modifies LDL to oxidized LDL that is taken up by macrophages in the intima of the vascular wall,
ultimately leading to the formation of foam cells. Later, cholesterol crystals (CCs) appear, which can stimulate
inflammatory responses and apoptosis in foam macrophages4. Oxidative stress also causes endothelial dysfunc-
tion, one of the early features of atherosclerosis5. Therefore, oxidative stress and inflammation are intimately
linked and play essential roles in the progression of atherosclerosis, and elucidation of the underlyingmechanisms
may lead to novel strategies for the prevention and treatment of atherosclerosis.
Oxidative stress results from the formation of reactive oxygen species (ROS), which are generated by various
pathways such as xanthine oxidoreductase (XOR), NADPH oxidase and mitochondrial respiratory enzymes6.
XOR is amolybdopterin-containing enzyme that oxidizes hypoxanthine to xanthine and finally to uric acid. XOR
exists in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH). Whereas XDH
uses NAD1 as an electron acceptor and produces NADH, XO mainly produces ROS such as superoxide and
hydrogen peroxide by preferentially using molecular oxygen as an electron acceptor7. XOR, as well as its meta-
bolite uric acid, are increased in atherosclerotic plaques compared to non-atherosclerotic carotid arteries, and
CCs, XOR and uric acid are co-localized in these plaques8. In addition, XOR inhibitors such as tungsten and
allopurinol inhibited the progression of atherosclerosis in ApoE2/2 mice. XOR is involved not only in the uptake
of oxidized LDL into macrophages but also in the induction of cytokines by soluble ligands such as LPS and
atherosclerotic serum9–11. Furthermore, ROS scavengers such as N-acetyl-L-cysteine (NAC) and apocynin inhib-
ited plaque formation and arterial inflammation in mice12–14. These findings strongly suggest that XO plays an
important role in the progression of atherosclerosis through ROS generation but definitive proof of its role in
atherosclerotic inflammation and the underlying mechanisms remain to be established.
Intracellular CCs are found in diet-induced atherosclerotic plaques and are composed of oxidized LDL that has
undergone endocytosis15,16. In macrophages, CCs activate the NLRP3-inflammasome resulting in IL-1b secre-
tion15–17. Intracellular ROS production has been shown to be critical for the NLRP3-dependent secretion of IL-1b
in response tomonosodium urate (MSU)18,19. It is not known if CC-induced pro-inflammatory cytokine release is
a XO- or ROS-dependent process.
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In this study, we examined the expression of XO in experimental
atherosclerosis, and studied the effects of febuxostat, a highly potent
inhibitor of XOR, both in vivo in the atherosclerosis model and in
vitro in CC-induced inflammation in macrophages.
Results
Xanthine oxidoreductase is increased in macrophages and endo-
thelial cells in ApoE2/2 mice. ApoE2/2 mice kept on a high
cholesterol diet for 12 weeks showed atherosclerotic features such
as the development of oil red O-positive staining and macrophage
infiltration of the aortic sinus compared to non-atherosclerotic WT
mice (Figure 1a). In aortic sinus from ApoE2/2 mice, XOR protein
was abundantly expressed in MOMA-2-positive macrophages
infiltrated into the plaque, whereas it was very low in non-
atherosclerotic aortic sinus from WT mice. In addition, in thoracic
aorta from ApoE2/2 mice, XOR was increased in endothelial cells
and smooth muscle cells (Figure 1b). Consistent with these findings,
XOR functional activity in aorta from ApoE2/2 mice was increased
compared to WT mice. Increased XOR activity was also observed in
the liver and plasma (Figure 1c and Table 1). As macrophages and
endothelial cells are involved in the process of plaque formation and
Figure 1 | Xanthine oxidoreductase is increased in macrophages and endothelial cells in ApoE2/2 mice. (a), Representative photographs of XOR
staining (top panels), MOMA-2 staining (middle panels), oil red O staining (middle panels), and hematoxylin-eosin staining (bottom panels) of aortic
sinus. Scale bars: 200 mm. (b), Representative photographs of XOR staining of thoracic aorta. Scale bars: 100 mm (upper panels) and 25 mm (lower
panels). (c), XOR activity in thoracic aorta (n 5 5) and liver (n 5 10) from WT and ApoE2/2 mice. Data are shown as mean 6 SEM.
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endothelial dysfunction, we hypothesized that XOR could play a role
in both these pathogenic processes of atherosclerosis.
Febuxostat inhibits plaque formation in ApoE2/2 mice. We exa-
mined whether febuxostat, a highly potent inhibitor of XOR,
inhibited plaque formation and macrophage infiltration. Febuxos-
tat (2.5 mg/kg/day) was administrated for 12 weeks in drinking
water to ApoE2/2 mice fed a high cholesterol diet and significantly
inhibited plasmaXOactivity at 12weeks compared to vehicle-treated
mice, showing that an effective dose of febuxostat was administrated.
On the other hand, febuxostat did not change body weight, total
cholesterol, triacylglycerol, NEFA, and glucose levels but increased
levels of HDL were found in ApoE2/2 mice (Table 1). Histologically,
both whole aorta and cross-sectional aortic sinus exhibited oil red
O-positive lesion areas which were significantly decreased in
febuxostat-treated ApoE2/2 mice, compared to the vehicle-treated
group (Figure 2). Febuxostat did not significantly reduce MOMA-2-
staining in ApoE2/2 mice. These results suggest that XOR inhibition
by febuxostat attenuated plaque formation, but not macrophage
infiltration in mice.
Febuxostat reduces the levels of ROS in the aortic wall of atheroscle-
rotic mice.We assessed the level of ROS expressed in the aortic sinus
by DHE staining, an indicator of oxidative stress, and found that
staining was significantly increased in aorta from ApoE2/2 mice
compared to that in WT mice (Figure 3). Febuxostat significantly
reduced DHE staining in ApoE2/2 mice. These data showed that
increased XO activity in ApoE2/2 mice is associated with increased
levels of ROS as well as the severity of atherosclerosis, and can be
attenuated by febuxostat.
Febuxostat inhibits the expression of pro-inflammatory genes in the
aorta. Next, we examined the mRNA expression of pro-inflammatory
Figure 2 | Febuxostat inhibits plaque formation in ApoE2/2 mice. (a), Representative photographs of en face oil red O staining of aorta (top panels),
cross-sectional oil red O staining (middle panels), cross-sectional MOMA-2 staining (middle panels), and cross-sectional hematoxylin-eosin staining
(bottom panels) of aortic sinus. Scale bars: 2 mm (top panels) and 200 mm (the other panels). (b), Quantitative analysis of en face oil red O-positive
area of aorta from vehicle-treated (n 5 10) and febuxostat-treated (n 5 10) ApoE2/2 mice. Data are shown as mean 6 SEM. *P, 0.05 versus vehicle-
treated group. (c), Quantitative analysis of cross-sectional oil red O-positive area of aortic sinus from vehicle-treated (n 5 19) and febuxostat-treated
(n 5 19) ApoE2/2 mice. Data are pooled from two independent experiments in which similar results were obtained, and shown as mean 6 SEM.
**P, 0.01 versus vehicle-treated group. (d), Quantitative analysis of cross-sectionalMOMA-2-positive area of aortic sinus from vehicle-treated (n5 15)
and febuxostat-treated (n5 15) ApoE2/2 mice. Data are pooled from two independent experiments in which similar results were obtained, and shown as
mean 6 SEM.
www.nature.com/scientificreports
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genes in the aorta (Figure 4). Expressions of MCP-1, IL-1a and IL-1b
have been reported to be associated with atherosclerosis20–22. In
addition, VCAM-1 mediates the migration of macrophages into
the tissue, and CD68 is a marker for macrophage lineage23. We
found significantly increased levels of MCP-1, IL-1a, IL-1b, CD68
and VCAM-1 mRNA in ApoE2/2 mice. Febuxostat treatment
significantly decreased MCP-1 expression, and a trend towards
decreased IL-1a, IL-1b and CD68 expression levels was also
Figure 3 | Febuxostat reduces the levels of ROS in the aortic wall of atherosclerotic mice. (a), Representative photographs of cross-sectional DHE
staining (top panels), DAPI staining (middle panels), and bright field (bottom panels) of aortic sinus. Dashed lines indicate aortic sinus lesion. Scale bars:
200 mm. (b), Quantitative analysis of DHE fluorescence intensity in aortic sinus from WT (n 5 10), vehicle-treated (n 5 8), and febuxostat-treated
(n 5 10) ApoE2/2 mice. Data are representative of two independent experiments in which similar results were obtained, and shown as mean 6 SEM.
####P , 0.0001 versus vehicle-treated WT, *P , 0.05 versus vehicle-treated ApoE2/2 mice.
Figure 4 | Febuxostat inhibits the expression of pro-inflammatory genes in the aorta. qRT-PCR analysis was performed using total RNA extracted from
aorta of vehicle-treated WT (n 5 10), vehicle-treated (n 5 10), and febuxostat-treated (n 5 9) ApoE2/2 mice. Data are pooled from two
independent experiments in which similar results were obtained, and shown as mean 6 SEM. #P, 0.05, ##P, 0.01, ###P, 0.001 versus vehicle-treated
WT mice, *P , 0.05 versus vehicle-treated ApoE2/2 mice.
www.nature.com/scientificreports
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observed. By contrast, VCAM-1 expression level was not affected. In
addition, we examined eNOS, a mediator of endothelial-dependent
relaxation and vascular protection24,25 and found that mRNA levels
of eNOS in ApoE2/2 mice were significantly enhanced by febuxostat.
Cholesterol crystals enhance macrophage inflammatory cytokine
secretion via XO and ROS. We hypothesized that CCs stimulate
macrophage pro-inflammatory cytokine release by inducing XO and
ROS production. BMDM were first primed with Pam3CSK4 for
activation, and then stimulated with CCs. Intracellular uric acid
levels were increased by CCs, suggesting that CCs increased purine
metabolism, leading to relative increase in endogenous XOR activity
(Figure 5a). As expected, febuxostat completely inhibited the
increased intracellular uric acid production (Figure 5a). CCs also
increased intracellular ROS generation by primed macrophages
(Figure 5b). This ROS induction was totally inhibited by NAC, a
ROS scavenger and also by febuxostat (Figure 5b). These results
indicated that CCs induced XO activity, leading to the increased
ROS level. We next tested whether CCs induced pro-inflammatory
cytokine release. The secretion of IL-1b by primed macrophages was
inhibited by caspase inhibitor z-VAD-fmk, by ROS inhibitors as well
as by febuxostat in a dose dependent fashion (Figure 5c). In addition,
we found that MCP-1, IL-1a and IL-6, which all play an important
role in atherosclerosis, were also induced by CC stimulation in
primed macrophages (Figure 5d–f). Although caspase inhibition
had a partial effect on IL-1a and MCP-1 secretion, it had no effect
on IL-6 secretion. Febuxostat dose-dependently decreased the release
of all these cytokines/chemokines, indicating that it inhibits the
release of both caspase-1-dependent and -independent molecules
(Figure 5c–f). The ROS scavengers NAC and apocynin
recapitulated the inhibitory effects of febuxostat on the secretion of
MCP-1, IL-1b, IL-1a and IL-6 (Figure 5c–f). In addition, it has been
reported that caspase-1-dependent cell death, called pyroptosis is
involved in plaque instability26. Febuxostat prevented lactate
dehydrogenase (LDH) release induced by CCs, suggesting that
febuxostat has no cytotoxicity per se and can inhibit pyroptosis
induced by CCs (Figure 5g). Taken together, these results
demonstrated that generation of ROS through XO activity is a
crucial mechanism in CC-induced cytokine and chemokine
production.
Discussion
The roles of XO and ROS in atherosclerosis have been well docu-
mented in previous studies9,10,12–14, but the mechanisms that drive
ROS generation as well as the consequences of its production are
not fully understood. In this study, we present data to show that the
development of atheroma in the aorta is accompanied by macro-
phage infiltration and co-localizes with areas of increased XO and
ROS activities. Inhibition of XO and ROS production by a potent
XOR inhibitor, febuxostat, attenuated not only the histological fea-
tures of atherosclerosis but also the production of pro-inflammatory
mediators in the aorta. Furthermore, CCs stimulate macrophages to
produce inflammatory mediators implicated in atherosclerosis via a
XOdependent ROS pathway. These findings suggest ROS generation
by XO links CC accumulation in the atheromatous plaque to local
inflammation, and its inhibition can attenuate the progression of
atherosclerosis.
Atheromatous plaques are formed by crystallization of soluble
oxidized LDL into CCs within macrophages15 and are inflammatory
lesions14. We found that CCs are potent inducers of the secretion of
inflammatory mediators such asMCP-1, IL-1a and IL-6 frommacro-
phages and confirmed that CCs induced macrophage IL-1b secretion
through caspase-1-dependent mechanisms. The importance of NLRP3/
caspase-1 in atherosclerosis has been questioned. NLRP32/2ApoE2/2
double-deficient mice have been reported to develop atherosclerosis
independently of inflammasome27. Conversely, less atherosclerotic
plaque was seen in NLRP32/2 bone marrow-transplanted LDLR
deficient mice or in caspase-12/2ApoE2/2 double-deficient mice15,28.
The reasons for these discrepancies are unclear, but suggest that
inflammation in atherosclerosis does not always require the
NLRP3-inflammasome.
Particulate DAMPs such as MSU crystals activate the NLRP3-
inflammasome through ROS-dependent mechanisms29. Macro-
phages exposed to CCs showed enhanced XO activity, evidenced
by increases in intracellular uric acid and ROS levels and ROS sca-
vengers and febuxostat inhibited IL-1b production induced by CCs.
We found that XO is themajor source of ROS inmacrophages and its
generation results not only in IL-1b release, but also the secretion of
IL-1a, IL-6 and MCP-1. These results were recapitulated in vivo, as
atheromatous plaques showed increased XO activity, ROS levels and
inflammatory cytokine expression. Both atherosclerosis and inflam-
mation were attenuated when the mice were treated with febuxostat.
Febuxostat itself had no effects on serum lipids in the animal model,
indicating that its effects were due to XO inhibition. Taken together,
we conclude that XO plays a fundamental role in atherosclerosis-
related inflammation through intracellular ROS accumulation in
macrophages, but not in lipid metabolism.
Both in vivo and in vitro, XO inhibition inhibited caspase-1-
dependent and -independent pro-inflammatory cytokine/chemo-
kine release. In vitro, CCs induced MCP-1, IL-1a and IL-6 release
from macrophages. The secretion of IL-6 is caspase-1-independent,
as it was not altered when z-VAD-fmk was added; whereas the
induction of IL-1a and MCP-1 was partially dependent on cas-
pase-1. In vivo, MCP-1 expression level was reduced when animals
were given febuxostat. We conclude that febuxostat as well as ROS
scavengers act on both caspase-1-dependent and -independent path-
ways of cytokine/chemokine release by CCs. Further studies are
required to clarify the underlying mechanisms of the involvement
of XO in caspase-1-dependent and -independent pathways.
We hypothesize that increased XO activity eventually causes
excess ROS formation, leading to tissue damage. In this context,
pharmacological inhibitors of XO, such as febuxostat, allopurinol
and oxypurinol, have been reported to have anti-inflammatory
effects in various diseases, most likely via inhibition of ROS produc-
tion. In addition, we recently demonstrated inhibitory effects of
febuxostat on the expression of cytokines/chemokines in vitro in
human and murine macrophages. This inhibitory effect was related
to intracellular ROS levels and not to uric acid levels11. On the other
hand, uric acid, which is one of the end-products of XOR, can act as
scavenger for peroxynitrite (PN). Thus, uric acid in the blood is
expected to contribute to the reduction of oxidative stress by PN.
Indeed, PN has been implicated in multiple sclerosis (MS) and its
animal model experimental allergic encephalomyelitis (EAE), and
uric acid has been reported to be reduced in the serum of patients
with multiple sclerosis (MS) and optic neuritis (ON). It has been
suggested that lower serum uric acid levels in MS patients may rep-
resent a loss of protection against PN. In accordance with this, uric
acid administration has been beneficial in EAE. However, some
recent studies failed to correlate uric acid serum levels and several
clinical parameters of MS and ON30,31. Stroke is also another disease
in which uric acid could play a protective role. However, the pro-
gnostic value of serum uric acid in acute ischemic stroke is contro-
versial. In one clinical study, increased uric acid serum levels are
associated with better outcome in patients with stroke32, whereas
in another study no association between serum uric acid levels and
both short- and long-term outcome in stroke was found33. Most
importantly, a causal relationship between increase in stroke and
decrease in uric acid levels by febuxostat treatment has not been
established and no exacerbations of inflammatory diseases were
reported in patients with febuxostat34,35.
Among clinically available XOR inhibitors, allopurinol as well as
febuxostat has been reported previously to be effective in mouse
www.nature.com/scientificreports
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Figure 5 | Cholesterol crystals enhance macrophage inflammatory cytokine secretion via XO and ROS. Primed BMDMwere stimulated for 30 min (a)
and (b) or 6 h (c–g)withCCs in the presence or absence of febuxostat. (a), The effect of CCs on intracellular uric acid level. Data are representative of three
independent experiments and are shown as mean 6 SEM. ##P , 0.01 versus vehicle/medium-treated, ***P , 0.001 versus vehicle/CC-treated group.
(b), The effect of CCs on intracellular ROS accumulation. Data are representative of three independent experiments and are shown as mean 6 SEM.
****P, 0.0001 versus vehicle/CC-treated group. (c–f), The effects of CCs on the productions of inflammatory mediators. Fx indicates febuxostat; NAC,
N-acetyl-L-cysteine (50 mM); Apo, Apocynin (500 mM); z-VAD, z-VAD-fmk (10 mM), respectively. Data are representative of three independent
experiments and shown asmean6 SEM. *P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001 versus vehicle/CC-treated group. (g), The effect of CCs on
LDH release. Data are representative of three independent experiments and shown as mean 6 SEM. ###P, 0.001 versus vehicle/medium-treated group,
**P , 0.01, ***P , 0.001 versus vehicle-treated group.
www.nature.com/scientificreports
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model of atherosclerosis9. Our recent studies showed that febuxostat
attenuated LPS-induced MCP-1 production11, and improved
endothelial dysfunction in ApoE2/2 mice (see Supplementary Fig.
S1 oneline). Febuxostat is 1000-fold more potent than allopurinol in
the inhibition of ROS or uric acid production by XO, and it can
completely inhibit ROS production by endothelium-bound XO
whereas allopurinol only has a partial effect36. In high-risk cardiac
surgery patients with hyperuricemia, febuxostat but not allopurinol
lowered oxidized LDL level, oxidative stress and pulse wave velo-
city37. These findings indicate that febuxostat has superior potency to
allopurinol for inhibition of XO-derived ROS production. Further-
more, the finding that febuxostat can inhibit the production of cas-
pase-1-dependent and -independent cytokine/chemokine makes it
an attractive therapeutic agent in atherosclerosis.
Methods
Animal experiments. Male apoE2/2 (B6.129P2-Apoetm1Unc/J) and wild-type (WT;
C57BL/6J) mice were purchased at 7 weeks of age from Jackson Laboratory (Bar
Harbor, ME). From 8 weeks of age, apoE2/2 mice were fed with western diet
containing 0.15% cholesterol and 40% fat (F2WTD; Oriental Yeast, Tokyo, Japan),
and administrated with drinking water containing 0.027 mg/mL of febuxostat (Teijin
Pharma Ltd., Tokyo, Japan) for 12 weeks. As non-atherosclerotic control, WT mice
were kept on normal diet for the same period. All experimental procedures were
conducted in accordance with the Guiding Principles for the Care and Use of
Laboratory Animals (Teijin Pharma Ltd.), and each experimental protocol was
approved by the Committee for Animal Experiments of the Teijin Institute for
Biomedical Research. All efforts were made to minimize suffering and minimize the
number of mice needed to assess statistical significance and experimental
reproducibility.
Histology and lesion analysis. For immunohistochemistry, aortic root was frozen in
O.C.T compound, cut into 10 mm serial section and stained with MOMA-2 antibody
(AbD serotec, Raleigh, NC) and XOR antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) for assessment of macrophage infiltration, and for examination of
XOR protein level, respectively. For quantification of atherosclerotic lesion, Oil Red
O-positive lesion surface areas on en face preparation of whole aorta were measured.
Briefly, aorta from root to the abdominal area was dissected and fixed with formalin,
and followed by removing the connective tissues carefully. Then, the entire aorta was
opened longitudinally, pinned en face, stained with Oil Red O (Wako, Osaka, Japan),
and photographed with digital camera. The total surface area and total Oil Red O-
positive lesion area were determined using WinROOF ver.6 (Mitani Corporation,
Tokyo, Japan). The extent of atherosclerotic lesion development was defined as the
percentage of total Oil Red O-positive lesion area over the total surface area. In
addition, frozen sections of aortic root were also stained with Oil Red O, and total Oil
Red O-positive lesion area was determined. For detection of superoxide, frozen
sections were stained with 10 mM of dihydroetidium (DHE; Wako) for 30 min,
followed by counterstaining and sealing with VECTASHIELDH Hard set Mounting
Medium with DAPI (Vector laboratories, Burlingame, CA). Fluorescence images
were obtained with BIOREVO BZ-9000 apparatus (KEYENCE, Japan), and
fluorescence intensity was analyzed with ImageJ software (NIH, Bethesda, MD).
Isometric tension measurements. Two murine aortic rings (2 mm length) were
prepared and set into magnus apparatus (Iwashiya Kishimoto Medical Instruments,
Kyoto, Japan) in Krebs-Henseleit solution (119 mMNaCl, 25 mMNaHCO3, 10 mM
glucose, 4.7 mM KCl, 1.2 mM MgSO47H2O, 1.2 mM KH2PO4, and 2.5 mM
CaCl22H2O) with 95% O2/5% CO2. After equilibration for 60 min, rings were
contracted twice with 60 mMKCl and once with 1 mMof phenylephrine (PE;Wako).
Then, the relaxation reaction was obtained by addition of acetylcholine (ACh; Sigma-
Aldrich, St. Louis, MO) to confirm the presence of endothelial cells. After washing,
cumulative addition of ACh (0.001–100 mM) to PE-precontracted ring was
performed to obtain endothelial cell-dependent relaxation. Cumulative addition of
sodium nitroprusside (SNP; 0.001–100 mM; Sigma-Aldrich) to PE-precontracted
ring was performed to obtain endothelial cell-independent relaxation.
Measurement of XO/XDH activity. XO/XDH activity in tissues or plasma was
measured with pterin-based assay as previously described38. For in vivo samples, aorta
or liver tissues were homogenized in 50 mM phosphate buffer (pH 7.4) containing
1 mM EDTA and protease inhibitor cocktail. Then, tissue homogenates or plasma
were reacted with 50 mM pterin (Sigma-Aldrich) for XO activity, or 50 mM pterin
plus 50 mMmethylene blue (Sigma-Aldrich) for XO plus XDH activity. Activity was
expressed as units/mL (plasma) or units/mg protein (tissue homogenate) using
buttermilk XO (Merck Millipore, Billerica, MA) as standard.
Blood parameters. Blood samples were collected 12 weeks after administration with
febuxostat. Plasma concentration of total cholesterol, HDL-cholesterol,
triacylglycerol, glucose, and NEFA were measured by enzymatic methods using
Hitachi 7180 autoanalyzer (Hitachi, Tokyo, Japan).
Quantitative real-time RT-PCR (qRT-PCR). Total RNA from aorta was extracted
using TRIzol reagent (Life Technologies, Carlsbad, CA) according to the
manufacturer’s instructions, and converted to cDNA using SuperScript VILO
MasterMix (Life Technologies). The cDNA was amplified using SYBRH Green (Life
Technologies) with gene-specific primers on ABI PRISM 7500 system (Life
Technologies). The oligonucleotide primers used in the experiments were listed in
Table 2. For data normalization, an endogenous control (36B4) was determined for
controlling the cDNA input and the relative units were calculated by a comparativeCt
method.
Preparation of cholesterol crystal. Sterile, pyrogen-free CCs were synthesized as
described previously15. Prior to experimentation, crystals were resuspended in
RPMI1640 medium (Life Technologies), grounded and sonicated for 30 min. As
expected from pyrogen-free crystals, these crystals contain no contaminants able to
prime cells, and consequently no IL-1b was detected into supernatants of unprimed
macrophages stimulated with CCs.
Bone marrow-derived macrophage preparation. Bone marrow cells were isolated
from the tibia and femurs of wild-type C57BL/6 mice. The isolated cells were
incubated for 7 days on Petri dishes with 30% L929 conditioned medium (source of
M-CSF), 10% FBS (PAA laboratories GmbH, Austria), 1% HEPES (Life
Technologies) and 1% penicillin-streptomycin (Life Technologies) in Dulbecco’s
Modified Eagle Medium (DMEM, Life Technologies) for differentiation into bone
marrow-derived macrophages (BMDM). After differentiation, the resulting BMDM
were detached using cold PBS, and plated for stimulation experiments with complete
Table 2 | Sequences of primer pairs used in this study
Genes Forward (59R 39) Reverse (59R 39)
MCP-1 GGAAAAGGTAGTGGATGCAATTAGC AACTGCATCTGCCCTAAGGTCT
IL-1a CGAAGACTACAGTTCTGCCATT GACGTTTCAGAGGTTCTCAGAG
IL-1b TCCAGGATGAGGACATGAGCAC GAACGTCACACACCAGCAGGTTA
eNOS GAGATCAAAGGGCTACAACCTG TAGAGATGGTCCAGTTGGGAG
CD68 TCAAACAGGACCTACATCAGAG GAAGGACACATTGTATTCCACC
VCAM-1 CCCAAACAGAGGCAGAGTGT CAGGATTTTGGGAGCTGGTA
36B4 GGCCCTGCACTCTCGCTTTC TGCCAGGACGCGCTTGT
Table 1 | Comparisons of body weight and plasma parameters in
WT, vehicle- or febuxostat-treated ApoE2/2 mice
Parameters
WT ApoE2/2 ApoE2/2
Vehicle Vehicle Febuxostat
BW (g) 29.3 6 0.4 36.1 6 1.6{ 37.5 6 0.9*
T chol (mg/dL) 69.2 6 2.8 1499.8 6 46.6* 1406.0 6 90.8*
HDL (mg/dL) 42.0 6 2.1 10.8 6 1.2* 14.4 6 1.01*
TG (mg/dL) 74.8 6 9.7 165.8 6 17.9{ 204.6 6 20.9*
NEFA (mg/dL) 405.6 6 31.0 698.6 6 55.6{ 681.8 6 46.4{
Glucose (mg/dL) 202.6 6 7.2 237.4 6 9.3{ 246.8 6 7.5{
XO activity (mU/mL) 62.3 6 1.8 87.4 6 1.9* 54.9 6 3.9 | |
Plasma was prepared after 12 weeks from vehicle-treated WT mice or from vehicle- or febuxostat-
treated ApoE2/2 mice. Values are mean 6 SEM. BW indicates body weight; T chol, total
cholesterol; HDL, high density lipoprotein; TG, triacylglycerol; NEFA, non-esterified fatty acid.
XOR activity in plasma was derived from XO, but not XDH. Samples numbers: n 5 20 for XO
activity and n 5 10 for the other parameters.
*P , 0.0001;
{P , 0.001;
{P , 0.01 vs. WT;
1P , 0.05;
| | P , 0.0001 vs. vehicle-treated ApoE2/2 mice.
www.nature.com/scientificreports
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RPMI1640 medium with 10% FBS, 1% HEPES and 1% penicillin-streptomycin (Life
Technologies).
Cell stimulation. BMDM were plated and left several hours in 96-well plates or 48-
well plates in complete medium. For experiments that required priming, cells were
stimulated overnight with 100 ng/mL of Pam3CSK4 (InvivoGen, San Diego, CA).
Cells were then incubated in incompletemedium (without FBS) with febuxostat at the
indicated concentrations, NAC (50 mM, Sigma-Aldrich), Apocynin (500 mM,
Sigma-Aldrich) or z-VAD-fmk (10 mM, ENZO Life Sciences, NewYork, NY) prior to
stimulation with CCs (1 mg/mL) for 6 h. As a positive control, MSU crystals at
250 mg/mL were used. At the end of the incubation, supernatants were collected and
stored at220uC for ELISA. Cell extracts were prepared for XOR activity and uric acid
measurement.
Measurement of LDH. LDH in supernatant was measured using CytoTox-ONETM
Homogeneous Membrane Integrity Assay kit (Promega, Madison, WI) according to
the manufacturer’s instructions. LDH release (%) was calculated by using the
following formula. LDH release (%) 5 [(value in sample) 2 (background)]/[(value in
Triton X-100-treated sample) 2 (background)].
ELISA. MCP-1, IL-1b, IL-6 ELISA kit (eBioscience, Inc., San Diego, CA) and IL-1a
ELISA kit (BioLegend, San Diego, CA) were used to measure the corresponding
chemokine/cytokines levels in supernatants according to the manufacturer’s
instructions.
Measurement of intracellular ROS level. Intracellular ROS level was measured with
Cell MeterTM Fluorimetric Intracellular Total ROS activity assay kit (AAT
BioquestH,Inc., Sunnyvale, CA) according to the manufacturer’s instructions. Briefly,
cells were loaded for 60 min with AmpliteTM ROS green. Then, cells were pretreated
for 10–15 minwith the indicated concentration of febuxostat orNAC, and stimulated
with 1 mg/mL CCs in HEPES-buffered saline (Life Technologies). Fluorescence
intensity on 490 nm (excitation) and 525 nm (emission) was measured with
fluorescence plate reader.
Measurement of intracellular uric acid. Intracellular uric acid was measured with
AmplexH Red Uric Acid/Uricase Assay Kit (Life Technologies) according to the
manufacturer’s instructions. Uric acid level was expressed as nmol/mg protein by
normalizing with protein concentration.
Statistic analysis. All data are expressed as mean 6 SEM. For two-group
comparisons, student’s t test was used. For multiple comparisons, one-way ANOVA
followed by a Dunnett’s test was used to compare each group versus a vehicle-treated
or medium group. All data were statistically analyzed using GraphPad PRISM
software version 6.01 (GraphPad, La Jolla, CA).Differences with a probability value of
,0.05 were considered significant.
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